

Carla Regina Andrighetti-Fröhner,^a Ricardo José Nunes,^a Luiz Everson da Silva,^b Cláudia Maria Oliveira Simões^c and Sabine Foro^{d*}

^aDepartamento de Química—UFSC, 88040-900 Florianópolis, SC, Brazil, ^bDepartamento de Química, Universidade Federal de Mato Grosso — UFMT — Cuiabá, MT, Brazil, ^cDepartamento de Ciências Farmacêuticas—UFSC, 88040-900 Florianópolis, SC, Brazil, and ^dClemens Schöpf-Institut für Organische Chemie und Biochemie, Technische Universität Darmstadt, Petersenstrasse 22, D-64287 Darmstadt, Germany

Correspondence e-mail: foro@tu-darmstadt.de

Key indicators

Single-crystal X-ray study
T = 299 K
Mean $\sigma(\text{C}-\text{C}) = 0.004 \text{ \AA}$
R factor = 0.047
wR factor = 0.130
Data-to-parameter ratio = 11.2

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

Pyridinium 4-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]-benzenesulfonate


In the title compound, $\text{C}_5\text{H}_6\text{N}^+\cdot\text{C}_{15}\text{H}_{11}\text{O}_4\text{S}^-$, the C—C—C—C torsion angle of $-166.9(2)^\circ$ between the 5-vinylbenzenesulfonate group and the phenyl ring indicates the nonplanarity of the system. The NH group of the pyridinium ring has an intermolecular contact with a sulfonyl O atom. Six intermolecular C—H \cdots O hydrogen bonds are also observed in the crystal structure.

Received 26 March 2007

Accepted 4 June 2007

Comment

Chalcones are natural compounds of the flavonoid family. Chemically, they consist of open-chain flavonoids in which the two aromatic rings are joined by a three-carbon α,β -unsaturated carbonyl system. They exhibit biological activities, the most important being oestrogenic, antifungal, antinociceptive, antibacterial, antiviral and anti-inflammatory (Dimmock *et al.*, 1999). Their antifungal and antileishmanial activities suggest that the mode of action of some chalcones is by inhibiting the activity of an enzyme that participates in the biosynthesis of ergosterol (Chan-Bacab & Pena-Rodriguez, 2001). We have investigated a series of novel synthetic chalcone derivatives for their trypanocidal and leishmanicidal properties (Lunardi *et al.*, 2003; Andrighetti-Fröhner *et al.*, 2003). In the light of this interest, we report here the crystal structure of the title compound, (I).



In (I), the 5-vinylbenzenesulfonate group is nearly planar, with a deviation from the mean plane of $0.112(2) \text{ \AA}$ for C7 and $-0.096(2) \text{ \AA}$ for C8. The C7—C8—C9—C10 torsion angle of $-166.9(2)^\circ$ between this group and the phenyl ring indicates the nonplanarity of the system. The C6—H6 \cdots O1^v=S1^v and C3—H3 \cdots O4^{vi}=C9^{vi} hydrogen bonds build bilayers of 4-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]benzenesulfonate anions perpendicular to the *a* axis and connected by a layer of pyridinium cations by the hydrogen bonds N1—H1N \cdots O3ⁱ=S1ⁱ, C16—H16 \cdots O1ⁱⁱ=S1ⁱⁱ, C20—H20 \cdots O1ⁱ=S1ⁱ, C17—H17 \cdots O2^{iv}=S1^{iv} and C19—H19 \cdots O2ⁱⁱⁱ=S1ⁱⁱⁱ. Details of the hydrogen bonding, including symmetry codes, are given in Table 1.

Experimental

The title compound (I) was prepared according to the literature procedure (da Silva *et al.*, 2006). Single crystals of (I) suitable for X-ray data collection were obtained by recrystallization from a methanol–dichloromethane solution (1:1).

Crystal data

$C_5H_6N^+ \cdot C_{15}H_{11}O_4S^-$	$V = 1815.5(4) \text{ \AA}^3$
$M_r = 367.41$	$Z = 4$
Monoclinic, $P2_1/c$	Cu $K\alpha$ radiation
$a = 17.034(2) \text{ \AA}$	$\mu = 1.80 \text{ mm}^{-1}$
$b = 9.0682(9) \text{ \AA}$	$T = 299(2) \text{ K}$
$c = 11.832(2) \text{ \AA}$	$0.50 \times 0.40 \times 0.35 \text{ mm}$
$\beta = 96.61(2)^\circ$	

Data collection

Enraf–Nonius CAD-4 diffractometer	2812 reflections with $I > 2\sigma(I)$
Absorption correction: none	$R_{\text{int}} = 0.021$
3698 measured reflections	3 standard reflections
3222 independent reflections	frequency: 120 min
	intensity decay: 1.0%

Refinement

$R[F^2 > 2\sigma(F^2)] = 0.047$	287 parameters
$wR(F^2) = 0.130$	Only H-atom coordinates refined
$S = 1.09$	$\Delta\rho_{\text{max}} = 0.63 \text{ e \AA}^{-3}$
3222 reflections	$\Delta\rho_{\text{min}} = -0.33 \text{ e \AA}^{-3}$

Table 1

Hydrogen-bond geometry (\AA , $^\circ$).

$D-H \cdots A$	$D-H$	$H \cdots A$	$D \cdots A$	$D-H \cdots A$
$N1-H1N \cdots O3^i$	0.97 (3)	1.86 (3)	2.790 (2)	159 (3)
$C16-H16 \cdots O1^{ii}$	0.88 (3)	2.44 (3)	3.260 (3)	156 (2)
$C19-H19 \cdots O1^{iii}$	0.95 (3)	2.42 (3)	3.324 (3)	161 (2)
$C17-H17 \cdots O2^{iv}$	1.00 (3)	2.48 (3)	3.224 (3)	132 (2)
$C20-H20 \cdots O2^j$	0.92 (3)	2.52 (3)	3.251 (3)	136 (2)
$C6-H6 \cdots O1^v$	0.93 (3)	2.40 (3)	3.303 (3)	164 (2)
$C3-H3 \cdots O4^{vi}$	0.93 (3)	2.42 (3)	3.275 (3)	152 (2)

Symmetry codes: (i) $x-1, -y+\frac{1}{2}, z+\frac{1}{2}$; (ii) $-x+1, y-\frac{1}{2}, -z+\frac{3}{2}$; (iii) $-x+1, y+\frac{1}{2}, -z+\frac{3}{2}$; (iv) $-x+1, -y, -z+1$; (v) $x, -y+\frac{1}{2}, z-\frac{1}{2}$; (vi) $-x+1, -y+1, -z+1$.

H atoms were located in difference maps and their positions refined [$C-H = 0.87(3)$ – $1.01(4) \text{ \AA}$, $N-H = 0.97(3) \text{ \AA}$], with $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{parent atom})$.

Data collection: *CAD-4-PC* (Enraf–Nonius, 1996); cell refinement: *CAD-4-PC*; data reduction: *REDU4* (Stoe & Cie, 1987); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *PLATON* (Spek, 2003); software used to prepare material for publication: *SHELXL97*.

The authors thank Professor Dr Hartmut Fuess, Technische Universität Darmstadt, for diffractometer time.




Figure 1

The molecular structure of (I), with the atom labelling. Displacement ellipsoids are drawn at the 50% probability level.




Figure 2

The molecular packing of (I), with hydrogen bonding shown as dashed lines. [Symmetry codes: (b) $x-1, -y+\frac{1}{2}, z+\frac{1}{2}$; (c) $-x+1, -y+1, -z+1$; (d) $x, -y+\frac{1}{2}, z-\frac{1}{2}$; (e) $-x+1, -y, -z+1$.]

References

- Andrighetti-Fröhner, C. R., Antonio, R. V., Creczynski-Pasa, T. B., Barardi, C. R. & Simões, C. M. O. (2003). *Mem. Inst. Oswaldo Cruz*, **98**, 843–848.
- Chan-Bacab, M. J. & Pena-Rodriguez, L. M. (2001). *Nat. Prod. Rep.* **18**, 674–688.
- Dimmock, J. R., Elias, D. W., Beazely, M. A. & Kandepu, N. M. (1999). *Curr. Med. Chem.* **6**, 1125–1149.
- Enraf–Nonius (1996). *CAD-4-PC*. Version 1.2. Enraf–Nonius, Delft, The Netherlands.
- Lunardi, F., Guzela, M., Rodriguez, A. T., Corrêa, R., Eger-Mangrich, I., Steindel, M., Grisard, E. C., Assrey, J., Calixto, J. B. & Santos, A. (2003). *Antimicrob. Agents Chemother.* **47**, 1449–1451.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
- Silva, L. E. da, Andrighetti-Fröhner, C. R., Nunes, R. J., Simões, C. M. O. & Foro, S. (2006). *Acta Cryst.* **E62**, o2104–o2105.
- Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.
- Stoe & Cie (1987). *REDU4*. Version 6.2c. Stoe & Cie GmbH, Darmstadt, Germany.